Serum Ferritin Independently Predicts the Incidence of Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus
Authors Wu YH, Wang SY, Li MX, He H, Yin WJ, Guo YH, Zhang HQ, Sun ZM, Zhang D, Wang X, Sun SY, Tang SX, Du R, Zhang CH
Received 22 August 2019
Accepted for publication 29 November 2019
Published 14 January 2020 Volume 2020:13 Pages 99—105
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Juei-Tang Cheng
Yun Hong Wu, Su Yuan Wang, Ming Xia Li, Hua He, Wei Jin Yin, Yan Hong Guo, Hui Qin Zhang, Zeng Mei Sun, Dan Zhang, Xi Wang, Shu Yao Sun, Shu Xi Tang, Rong Du, Cheng Hui Zhang
Department of Endocrinology and Metabolism, Hospital of Chengdu Office of People’s Government of Tibetan Autonomous Region, Chengdu, People’s Republic of China
Correspondence: Cheng Hui Zhang
Department of Endocrinology and Metabolism, Hospital of Chengdu Office of People’s Government of Tibetan Autonomous Region, No. 20 Ximianqiao Street, Chengdu, Sichuan 610041, People’s Republic of China
Aim: This study aimed to determine whether serum ferritin (SF) is an independent risk factor of the incidence of chronic kidney disease (CKD) and rapid renal function decline (RFD) in male Tibetan patients with type 2 diabetes mellitus (T2DM).
Methods: We performed a retrospective cohort study that included 191 male Tibetan patients with T2DM without CKD. Patients were divided into three groups according to the level of SF. The following outcomes were measured: cumulative incidence of chronic kidney disease [i.e. estimated glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m 2 and/or urinary albumin/creatine ratio (ACR) ≥ 30 mg/g] and RFD (i.e. decrease in eGFR of ≥ 25% from baseline or a decline rate of ≥ 3 mL/min per 1.73 m 2 annually).
Results: In total, over a median follow-up period of 23 months, 30 (15.7%) and 89 patients (46.6%) developed CKD and RFD. In multivariable Cox models, a 100 ng/mL increment in SF was associated with a 1.12-fold (95% CI: 1.02– 1.24) higher adjusted risk for incidence of CKD. The adjusted-HR of CKD was 1.31 (95% CI: 0.38– 4.53) and 2.92 (95% CI: 0.87– 9.77) for those in tertile 2 and tertile 3, respectively, compared with the patients in tertile 1. However, SF was not significantly associated with RFD (adjusted-HR: 1.06, 95% CI: 0.99– 1.14).
Conclusion: Serum ferritin independently predicts the incidence of CKD in male Tibetan patients with T2DM. High levels of serum ferritin may play a role in the pathogenesis leading to the development of CKD in T2DM.
Keywords: serum ferritin, chronic kidney disease, type 2 diabetes mellitus
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]